Log In
BCIQ
Print this Print this
 

Clarinex Reditabs, desloratadine

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionOrally disintegrating, once-daily, combination of antihistamine and decongestant
Molecular Target Histamine H1 receptor (HRH1)
Mechanism of ActionHistamine H1 receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationRhinitis
Indication DetailsTreat perennial allergic rhinitis (PAR) and seasonal allergic rhinitis (SAR) and chronic idiopathic urticaria (CIU) in adults and children 6 years of age or older
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today